Examples of autoantibodies.
Autoantibodies are characteristic features of autoimmune diseases (Table 1). In organ or tissue-specific autoimmune diseases, autoantibodies against cell-surface molecules are usually observed. These antibodies (Abs) stimulate or damage the target cells and cause organ- or tissue-specific diseases. In systemic autoimmune diseases, in addition to anti-cell-surface molecule Abs, Abs against intracellular molecules are frequently observed although B cell tolerance to intracellular molecules is strictly enforced in normal subjects. Some indicate high disease specificity with a high incidence rate. Therefore, such Abs may be closely associated with development of the disease as well as with disease activity. However, it is not known how or why Abs against intracellular molecules are generated.
2. Role of cell death in the generation of anti-intracellular molecule antibodies
Cell death, including apoptosis and necrosis, represents a possible source of exposure of intracellular molecules outside the cell. For example, low – intermediate doses (< 35 mJ/cm2) of ultraviolet B (UVB) induce apoptosis of keratinocytes, resulting in translocation of native DNA, Ku, and Sm to the cytoplasmic membrane, while a high dose (80 mJ/cm2) of UVB induces necrosis, resulting in discharge of all of the cell compartments . Intracellular molecules are exposed on the surface blebs of apoptotic cells (apoptotic blebs) . Apoptotic blebs contain fragmented endoplasmic reticulum (ER), ribosomes, ribonucleoprotein, nucleosomal DNA, Ro, La, small nuclear ribonucleoproteins, etc. Autoantigens receive various epigenetic modifications (acetylation, methylation, phosphorylation, dephosphorylation, ADP-ribosylation, ubiquitination, oxidation, transglutamination, citrullination, SUMOylation, etc) during apoptotic cell death . In the case of cytotoxic granule-mediated cell death, granzymes plays an important role in cleavage of autoantigens . These epigenetic modifications may alter preexisting epitopes, expose cryptic epitopes, or form novel epitopes, and may contribute to bypassing tolerance to autoantigens . Normally, apoptotic cells are quickly eliminated by professional phagocytes. Delay of apoptotic cell clearance not only increases the time of exposure of intracellular molecules to the immune system but also changes the degree of modification of these molecules, which alters their antigenicity. When clearance fails, apoptotic cells enter the stage of secondary necrosis. The ability to cause inflammation depends on the stage of cell death . Damage-associated molecular patterns (DAMPs), such as HMGB1, SAP130, etc., are released from late apoptotic/necrotic cells into the extracellular space [7-9]. DAMPs activate Toll-like receptors and act as intrinsic adjuvants, resulting in inflammation and initiation of the host immune system. Thus, delay of apoptotic cell clearance increases the risk of an autoimmune response.
|1. Organ or tissue-specific autoimmune diseases|
a. Anti-cell-surface molecules
|TSH receptor*||TSH receptor||Graves’ disease|
|GAD||glutamic acid decarboxylase||Diabetes mellitus type I|
|myelin associated protein||myelin||Multiple sclerosis|
|b. Anti-intracellular molecules|
|thyroid microsomal||thyroid microsomal||Hashimoto’s thyroiditis|
|thyroid peroxidase||thyroid peroxidase||Hashimoto’s thyroiditis|
|2. Systemic autoimmune diseases|
a. Anti-cell-surface molecules
|PDGFreceptor||PDGF receptor||Systemic sclerosis|
|b. Anti-intracellular molecules|
3. Abnormalities related to apoptosis in SLE
There are many lupus autoantibodies that bind to autoantigens of apoptotic cells . In SLE, defective clearance of apoptotic cells has been reported. As a result, high levels of circulating early apoptotic cells are found in SLE . T-lymphocytes , macrophages/monocytes [13,14], neutrophils , and endothelial cells  are included among the increased numbers of apoptotic cells. Monocytes and granulocytes, which take up autoantibody remnants of secondary necrotic cell complex, secrete inflammatory cytokines in SLE . These phenomena threaten self-tolerance and are likely involved in the production of lupus autoantibodies [18,19]. The reason for defective apoptotic cell clearance in SLE has yet to be elucidated. It has been suggested that the efficacy of clearance is affected by the cell death trigger, but there have been no reports related to SLE from this viewpoint . Anti-class A scavenger receptor autoantibodies from patients with SLE impair the clearance of apoptotic debris by macrophages . However, the mechanism of autoantibody production is not yet known.
In SLE, the response to early apoptotic cells is also abnormal. Under normal conditions, macrophages secrete antiinflammatory cytokines (IL-10, TGF-β, PGE2, etc.) to send “tolerate me” signals after ingestion of apoptotic cells . Monocytes from healthy controls showed prominent TGF-β secretion and minimal TNF-α production, but monocytes from SLE patients show prominent TNF-α production and diminished TGF-β secretion . The authors speculated that this abnormal response may be an intrinsic property of lupus monocytes.
Recent studies have highlighted the role of neutrophils in the pathogenesis and manifestations of SLE . NETosis is a process characterized by the formation of neutrophil extracellular traps (NETs) . NETs become not only a source of intracellular molecules but also immunogens for lupus autoantibodies . Low-density granulocytes (LDGs), an abnormal subset of neutrophils, were identified among the PBMCs derived from patients with SLE . LDGs secrete type I interferons (INFs), have endothelial cytotoxicity, and have higher capacity to form NETs . Degradation of NETs is impaired in patients with SLE . NETs activate complement and deposited C1q inhibits NET degradation . These phenomena increase NETs and may contribute to the production of autoantibodies, including anti-DNA Abs.
It has recently been demonstrated that the source of intracellular molecules is microparticles (MPs), which are small membrane-bound vesicles . MPs, which emerge from the cell membrane during cell activation and apoptosis, contain a variety of cellular components, including nucleic acids . MPs become antigenic targets of anti-DNA Abs, form huge immune complexes in the plasma of patients with SLE, and induce complement activation [33,34].
4. Anti-dsDNA Abs
4.1. Brief historical aspects of anti-dsDNA Abs
SLE is characterized by the production of a variety of autoantibodies. Especially, anti-dsDNAAbs are the most characteristic of SLE and contribute to the pathogenesis of lupus nephritis. In general, anti-dsDNA Abs are specific for SLE and the anti-dsDNA Abs titer is closely correlated to the activity of lupus nephritis . A proportion of anti-dsDNA Abs are directly involved in immune complex-mediated glomerulonephritis . Thus, the trigger of anti-DNA response may be closely related to the pathogenesis of SLE. However, mammalian native dsDNA is not immunogenic, suggesting that DNA itself does not act as a triggering or driving antigen . The origin of anti-DNA Abs is a long-standing enigma.
Anti-dsDNA responses can be evoked by dsDNA with the aid of a carrier, such as the 27-amino acid nucleic acid-binding Fus1 peptide , polyoma BK virus large T Ag , or DNaseI-dsDNA complex  which have been shown to induce production of anti-dsDNA Abs in mice, suggesting a possible role of excess amounts of DNA – protein complex in disruption of tolerance to DNA. Nucleosomes have been suggested as possible Ags responsible for triggering of anti-dsDNA Abs [41,42]. Crude nucleosomes or crude histones  have been shown to induce production of anti-dsDNA Abs in mice. Mononucleosome-reactive Th clones augment the production of IgG autoantibodies to dsDNA, histones, and histone – DNA complex. However, immunization of SNF1 mice with pure mononucleosomes did not elicit production of IgG anti-dsDNA Abs . HMGB1 – nucleosome complexes derived from apoptotic cells, but not HMGB1-free nucleosomes, elicited IgG anti-dsDNA Abs in BALB/c mice although their titer was not high, suggesting that adjuvants such as HMGB1 are necessary to break tolerance to dsDNA in non-autoimmune mice .
Another possible mechanism is molecular mimicry. Some mouse or human monoclonal anti-DNA Abs have been shown to cross-react with non-nucleic acid self-Ags, such as extracellular matrix protein HP8 , heterogeneous nuclear ribonucleoprotein A2 , NR2 glutamate receptor , α-actinin [48,49], ribosomal protein S1 , and phospholipids, including cardiolipin . However, it is not yet known whether these molecules can elicit anti-DNA responses.
The peptide, DWEYSVWLSN, is recognized by the R4A mouse monoclonal anti-dsDNA Ab . Immunization with this peptide elicited anti-dsDNA Ab production and caused deposition of IgG in glomeruli in normal mice . These observations indicate that a non-nucleic acid Ag can elicit production of anti-DNA Abs and cause renal disorder in normal animals. However, no proteins containing this peptide sequence have been reported to date.
It should be noted that immunization with recombinant EBNA-1 protein elicited anti-EBNA-1 Abs that cross-react with dsDNA, suggesting molecular mimicry between the viral antigen and dsDNA . However, nephritogenicity of the anti-EBNA-1/dsDNAAbs has not been reported.
4.2. Cross-reactive antigen of the O-81 human nephritogenic anti-DNA mAb
We prepared human monoclonal anti-DNA Ab, O-81, which binds strongly to single-stranded DNA (ssDNA) and moderately to dsDNA, and demonstrated that the O-81 idiotype (Id) is distributed among IgG anti-DNA Abs of circulating immune complexes as well as lupus glomerular deposits [55-58]. The intravenous infusion of IgG isotype anti-DNA Abs expressing O-81 Id also caused glomerular IgG deposition in SCID mice . The VH region of O-81 Ab contains many somatic mutations . Similarly, the VH regions of O-81 Id-positive B cells in patients with SLE were shown to already contain somatic mutations . These observations prompted us to explore the triggering Ags for human nephritogenic anti-DNA Abs using the O-81 Ab.
[Methods] The cells were fixed in 50% acetone/50% methanol for 20 min at –20°C and blocked with 5% normal goat serum and 3% BSA in PBS overnight at 4°C. The cells were then incubated with HT2 mouse monoclonal IgG1 anti-Herp Ab or mouse IgG1 as an isotype control for 1 h at room temperature followed by incubation with FITC-conjugated goat F(ab') 2 anti-mouse IgG Ab (KPL, Gaithersburg, MD) for 1 h at room temperature .
We found that the O-81 Ab specifically cross-reacts with human homocysteine-induced endoplasmic reticulum protein (Herp) . Anti-dsDNA Abs purified from the sera of SLE patients bound to Herp, and anti-Herp Abs purified from the sera of SLE bound to dsDNA . The production of Herp is induced by endoplasmic reticulum (ER) stress. The PBLs from subjects in active SLE, especially at the time of onset or flare-up of the disease, tended to show Herp expression . The expression of Herp was also observed in the lymph node of an untreated patient with active SLE, indicating that Herp can be exposed to the immune system in lymph nodes where Ag recognition occurs (Figure 1).
Excessive ER stress is known to induce apoptosis [64,65]. Herp can be exposed on apoptotic blebs of ER stress-induced apoptotic cells . Many apoptotic cells expressing Herp were observed in the peripheral blood mononuclear cells (PBMCs) of patients with active SLE, but not normal control subjects . This observation is compatible with those reported previously . These results suggest that Abs against Herp on ER stress-induced apoptotic cells may become anti-Herp/dsDNA cross-reactive Abs, i.e., initial anti-dsDNA Abs.
4.3. Antigenicity of Herp for anti-dsDNA Ab production in mice
Immunization of normal BALB/c mice with Herp elicited anti-dsDNA Abs and caused glomerular IgG deposition . However, urinary protein level did not increase and overt nephritis did not develop. The pathological changes in the kidneys in Herp-immunized BALB/c mice went no further than silent lupus nephritis.
Nucleosomes, which are major autoantigens in SLE, are exposed at the apoptotic cell surface [66,67]. Anti-nucleosome Abs are present in SLE at a rate of more than 50% and they have been linked to lupus nephritis . Nucleosomes and histones are present in glomerular deposits . Nucleosomes bind to glomerular endothelial cells and serve as targets for anti-nucleosome Abs . Therefore, a portion of anti-nucleosome Abs may be involved in lupus nephritis . However, even oligonucleosomes are much less effective than Herp in inducing anti-nucleosome Abs as well as anti-dsDNA Abs . Therefore, to reproduce overt lupus nephritis, BALB/c mice were immunized with Herp followed by immunization with oligonucleosomes. In this procedure, both anti-dsDNA Ab and anti-nucleosome Ab-producing clones induced by Herp may be able to recognize oligonucleosomes easily. The production of anti-dsDNA Abs and glomerular IgG deposition were observed in all mice. In addition, overt nephritis with significant proteinuria occurred in one mouse (Figure 2). Although further investigations are in progress to define the mechanisms, it was speculated that (i) the Herp-induced anti-dsDNA Abs efficiently bound to nucleosomes and formed pathogenic immune complexes, and (ii) affinity maturation and epitope spreading of Herp-induced anti-dsDNA Abs occurred by nucleosomes.
[Methods] Five 6-week-old female BALB/c mice were immunized intraperitoneally with 100 μg of Herp on days 0 and 10 and 50 μg of Herp on day 20, followed by immunization with 10 μg of oligonucleosomes on days 30, 40, and 50. Preparation of Herp and oligonucleosomes was described previously . Fresh-frozen tissue sections 4 μm thick were fixed in 100% acetone for 10 min at 4°C and blocked with 5% normal goat serum and 3% BSA in PBS overnight at 4°C. Sections were stained with FITC-conjugated goat F(ab')2 anti-mouse IgG Ab (KPL) for 1 h at room temperature.
4.4. Antigenicity of Herp for anti-dsDNA Ab production in humans
To examine whether Herp can be an antigen for anti-dsDNA Ab production in humans, ELISPOT was performed using PBMCs (representative cases are shown in Figure 3). The number of spots increased when the PBMCs were incubated with Herp, but not with dsDNA, in 4 of 6 untreated active SLE patients (Figure 3A); in 2 of these 4 positive cases, a few spots were observed even in wells without stimulation (Figure 3B). The remaining two cases showed no spots (Figure 3C). On the other hand, no spots were detected in the PBMCs from nine treated active SLE patients, eight inactive SLE patients, and five normal control subjects (data not shown). These results suggest that Herp can stimulate anti-dsDNA antibody-producing clones but this stimulation is cancelled by immunosuppressive therapy.
[Methods] Approximately 1106 PBMCs in 20% fetal calf serum (FCS)-supplemented RPMI 1640 (20% FCS-RPMI 1640) were cultured for 5 days with or without 2 μg/mL Herp, or 10 μg/mL dsDNA. For preparation of dsDNA, calf thymus DNA (Invitrogen, Carlsbad, CA) was pretreated with S1 nuclease (Takara Bio, Otsu, Japan) to remove single-stranded DNA (ssDNA) according to the manufacturer’s instructions. Multiscreen 96-well filtration plates (Millipore, Billerica, MA) were coated with 10 mg/mL protamine overnight at 4°C, and washed with PBS followed by coating with 10 μg/mL dsDNA in PBS for 2 h at room temperature. Following blocking with 20% FCS-RPMI 1640, the cultured PBMCs in 20% FCS-RPMI were plated at 1×105 cells/well and cultured for 24 h. After washing the cells with PBS, goat alkaline phosphatase-conjugated anti-human IgG antibodies (diluted 1:10000; Sigma-Aldrich, St. Louis, MO) were added and the wells were incubated for 1 h at room temperature. Following a further wash, the spots were visualized using NBT-5-bromo-4-chloro-3-indolyl phosphate substrate (Sigma-Aldrich).
5. Anti-single-stranded DNA (ssDNA) Abs
The mechanism involved in the production of anti-ssDNA Abs has yet to be elucidated. As ssDNA can have multiple conformational epitopes and all Abs that bind to ssDNA are called anti-ssDNA Abs, these Abs are highly heterogeneous and display low disease specificity. However, the susceptibility of lupus-inducing drugs to anti-ssDNA Ab production is very high. In such cases, there may be a unique mechanism of anti-ssDNA Ab production, as the chemical structures and pharmacological actions of lupus-inducing drugs are known to be highly diverse [72,73]. As higher risk drugs include procainamide and hydralazine, which inhibit DNA methylation, hypomethylation may be one of the causes of anti-ssDNA Ab production, but its precise mechanism remains unknown [74-76].
Immunization with Herp elicits production of not only anti-dsDNA antibodies but also anti-ssDNA antibodies in BALB/c mice. Among several anti-Herp mAbs established in our laboratory, the HT4 anti-Herp mAb cross-reacts specifically with ssDNA . The epitope of the HT4 mAb on Herp, EPAGSNR, was identified by screening a synthetic peptide library. The binding of HT4 mAb to the peptide was competitively inhibited by ssDNA. Immunization of the epitope peptide elicited anti-ssDNA Abs in BALB/c mice. Treatment with chlorpromazine, procainamide, and hydralazine induced Herp expression and apoptosis in HeLa cells. These findings suggest that (i) ER stress and apoptosis by drugs and (ii) molecular mimicry between Herp and ssDNA are involved in anti-ssDNA antibody production in drug-induced lupus.
6. Postulated mechanism of anti-DNA Ab generation
Autoimmunity is associated with both genetic predisposition and environmental factors . The monozygotic disease concordance rate ranges from 24% to 57% (and not 100%) for SLE . Most patients with SLE are non-familial sporadic cases. That is, environmental etiologies of SLE may be common. It is well known that environmental factors such as viral infection, UV exposure, chemicals, etc., can trigger clinical onset or flare of SLE [80,81]. However, little is known regarding how those factors elicit anti-DNA antibody production in vivo. These factors, i.e., cell stressors, affect the expression patterns of cellular proteins, resulting in ER stress in some cases.
What is a practical model of this hypothesis? Natural infection with viruses can cause ER stress on a large scale in vivo . ER stress has been shown to increase when viral proteins are produced at high levels, e.g., in virion formation during the active lytic cycle of infection. Epstein–Barr virus (EBV) infection has been suggested to have a causative role in SLE [82,83]. The titers of anti-EBV Abs in SLE patients are higher than those of healthy controls . Kang et al. reported that: (i) patients with SLE had an approximately 40-fold increase in EBV viral load compared with controls; (ii) the frequency of EBV-specific CD69+ CD8+ T cells producing IFN-γ was higher in patients with SLE than in controls, but the frequency of EBV-specific CD69+ CD4+ T cells producing IFN-γ was lower in patients with SLE than in controls; and (iii) the EBV viral loads were positively correlated with the frequency of EBV-specific CD69+ CD8+ T cells but inversely correlated with the frequency of EBV-specific CD69+ CD4+ T cells . Larsen et al. reported that EBV-specific CD8+ T cell responses in patients with SLE are functionally impaired . The defective control of latent EBV infection in patients with SLE may result in recurrent reactivation of EBV. In fact, aberrant expression of BZLF1, which is a hallmark of EBV lytic infection, has been detected in the PBMCs of SLE patients . In primary EBV infection, EBV infects tonsillar B cells in which lytic replication occurs, and differentiation of latently EBV-infected B cells to plasma cells in lymphoid tissues is associated with induction of the EBV lytic cycle . Herp is expressed in BZLF1-positive EBV-infected B cells (Figure 4).
[Methods] EBV-transformed B cells were fixed in 50% acetone/50% methanol for 20 min at –20°C and blocked with 5% normal goat serum and 3% BSA in PBS overnight at 4°C. The cells were stained with DAPI. The cells were then co-stained with HT4 mouse IgG2a anti-human Herp mAb and mouse IgG1 anti-BZLF1 mAb (Dako, Glostrup, Denmark) for 1 h at room temperature followed by co-staining with rhodamine-conjugated goat anti-mouse IgG2a Ab (Santa Cruz Biotechnology, Santa Cruz, CA) and FITC-conjugated goat anti-mouse IgG1 Ab (Santa Cruz Biotechnology) for 1 h at room temperature.
ER stress, which is induced by the production of viral proteins, causes EBV lytic replication, resulting in the release of virions and intracellular molecules . The Herp produced in cells entering the lytic phase of EBV infection can be recognized by the immune system in lymphoid tissues. In addition, EBV-encoded latent membrane protein 2A (LMP2A) induces hypersensitivity to TLR stimulation, leading to activation of autoreactive B cells through the BCR/TLR pathway . Immunization with the membrane fraction of EBV-transformed B cells elicited anti-dsDNA Abs as well as anti-Herp Abs and causes glomerular IgG deposition in BALB/c mice . These observations support the hypothesis that EBV infection may be a trigger of SLE.
The results of the present study led to the following hypothesis in which cell stress triggers an anti-DNA response via Herp in normal individuals: ER stress by environmental factors Herp expression recognition by the immune system of minor epitope(s) mimicking ssDNA|or dsDNA anti-Herp/ssDNA or dsDNA cross-reactive Abs (initial anti-ssDNA or anti-dsDNA Abs) anti-DNA Ab – DNA complex, anti-DNA Ab – nucleosome complex ? tissue injury (Figure 5). After the initial production of anti-Herp/DNA Abs, the production of the Abs is stimulated whenever ER stress-induced apoptosis occurs, and the cause of ER stress is not restricted. Repeated cell stress during daily life may strengthen this pathway. Herp is a good candidate as a link between common environmental factors and the etiology of SLE.
As dead cells are not only a source of intracellular antigens but also a source of proinflammatory molecules, it is likely that they play an important role in the generation of nephritogenic anti-dsDNA Abs. Herp was identified as a molecule directly involved in cell stress/death as the cause of anti-dsDNA Ab production. Further investigations are therefore needed to clarify the relationship between cell stress/death and the etiology of SLE.
Caricchio R. Mc Phie L. Cohen P. L. 2003 Cell Death and Anti-DNA AntibodiesJ. Immunol. 171 5778 5786
Casciola-Rosen L. A. Anhalt G. Rosen A. 1994 Cell Death and Anti-DNA AntibodiesJ. Exp. Med. 179 1317 1330
Utz P. J. Gensler T. J. Anderson P. 2000Death, autoantigen modifications, and tolerance. Arthritis Res. 2 101 114
Darrah E. Rosen A. 2010 Cell Death and Anti-DNA AntibodiesCell Death Differ. 17 624 632
Brooks W. H. Le Dantec C. Pers J. O. Youinou P. Renaudineau Y. 2010Epigenetics and autoimmunity. J. Autoimmun. 34: J 207J219.
Poon IK, Hulett MD, Parish CR 2010 Cell Death and Anti-DNA AntibodiesCell Death Differ. 17 381 397
Chen G. Y. Nuñez G. 2010 Cell Death and Anti-DNA AntibodiesNat. Rev. Immunol. 10 826 837
Pisetsky D. 2011 Cell Death and Anti-DNA AntibodiesSwiss Med. Wkly. 141: w13256 EOF
Harris H. E. Andersson U. DS Pisetsky 2012 Cell Death and Anti-DNA AntibodiesNat Rev Rheumatol 8 195 202
Huggins M. L. Todd I. MA Cavers Pavuluri. S. R. Tighe P. J. Powell R. J. 1999 Cell Death and Anti-DNA AntibodiesClin. Exp. Immunol. 118 322 328
Perniok A. Wedekind F. Herrmann M. Specker C. Schneider M. 1998 Cell Death and Anti-DNA Antibodies 7 113 118
K( Gröndal G. Traustadottir K. H. Kristjansdottir H. Lundberg I. Klareskog L. Erlendsson K. Steinsson 2002 Cell Death and Anti-DNA Antibodies 11 435 442
Ren Y. Tang J. Mok M. Y. Chan A. W. Wu A. Lau C. S. 2003 Cell Death and Anti-DNA AntibodiesArthritis Rheum. 48 2888 2897
MJ Kaplan Lewis. EE Shelden E. A. Somers E. Pavlic R. Mc Cune W. J. Richardson B. C. 2002 Cell Death and Anti-DNA AntibodiesJ. Immunol. 169 6020 6029
Courtney P. A. Crockard A. D. Williamson K. Irvine A. E. Kennedy R. J. Bell A. L. 1999 Cell Death and Anti-DNA AntibodiesAnn. Rheum. Dis. 58 309 314
Kaplan MJ 2004 Cell Death and Anti-DNA AntibodiesClin. Immunol. 112 210 218
Muñoz L. E. Janko C. Grossmayer G. E. Frey B. Voll R. E. Kern P. Kalden J. R. Schett G. Fietkau R. Herrmann M. Gaipl U. S. 2009Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosus. Arthritis Rheum. 60 1733 1742
Muñoz L. E. Lauber K. Schiller M. AA Manfredi Herrmann. M. 2010 Cell Death and Anti-DNA AntibodiesNat Rev Rheumatol 6 280 289
Muñoz L. E. Janko C. Schulze C. Schorn C. Sarter K. Schett G. Herrmann M. 2010Autoimmunity and chronic inflammation- two clearance-related steps in the etiopathogenesis of SLE. Autoimmun. Rev. 10 38 42
Wiegand U. K. Corbach S. Prescott A. R. Savill J. BA Spruce 2001 Cell Death and Anti-DNA AntibodiesCell Death Differ. 8 734 746
Chen X. W. Shen Y. Sun C. Y. Wu F. X. Chen Y. Yang C. D. 2011 Cell Death and Anti-DNA AntibodiesArthritis Res. Ther. 13: R9 EOF
Voll R. E. Herrmann M. Roth E. A. Stach C. Kalden J. R. Girkontaite I. 1997Immunosuppressive effects of apoptotic cells. Nature 390 350 351
Sule S. Rosen A. Petri M. Akhter E. Andrade F. 2011 Cell Death and Anti-DNA Antibodies e17495 EOF
Kaplan MJ, 2011 Cell Death and Anti-DNA AntibodiesNat Rev Rheumatol 7 691 699
Amulic B. Cazalet C. Hayes G. L. Metzler K. D. Zychlinsky A. 2012 Cell Death and Anti-DNA AntibodiesAnnu. Rev. Immunol. 30 459 489
Liu C. L. Tangsombatvisit S. Rosenberg J. M. Mandelbaum G. Gillespie E. C. Gozani O. P. AA Alizadeh Utz. P. J. 2012 Cell Death and Anti-DNA AntibodiesArthritis Res. Ther. 14: R25.
Denny M. F. Yalavarthi S. Zhao W. Thacker S. G. Anderson M. Sandy A. R. Mc Cune W. J. MJ Kaplan 2010 Cell Death and Anti-DNA AntibodiesJ. Immunol. 184 3284 3297
MJ( Villanueva E. Yalavarthi S. Berthier C. C. Hodgin J. B. Khandpur R. Lin A. M. Rubin C. J. Zhao W. Olsen S. H. Klinker M. Shealy D. Denny M. F. Plumas J. Chaperot L. Kretzler M. Bruce A. T. Kaplan M. 2011Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J. Immunol. 187 538 552
Hakkim A. Fürnrohr B. G. Amann K. Laube B. Abed U. A. Brinkmann V. Herrmann M. Voll R. E. Zychlinsky A. 2010 Cell Death and Anti-DNA AntibodiesProc. Natl. Acad. Sci. U. S. A. 107 9813 9818
Leffler J. Martin M. Gullstrand B. Tydén H. Lood C. Truedsson L. AA Bengtsson Blom. A. M. 2012 Cell Death and Anti-DNA AntibodiesJ. Immunol. 188 3522 3531
Beyer C. DS Pisetsky 2010 Cell Death and Anti-DNA AntibodiesNat Rev Rheumatol 6 21 29
DS Pisetsky Gauley. J. Ullal A. J. 2011 Cell Death and Anti-DNA AntibodiesImmunol. Res. 49 227 234
Ullal A. J. Reich C. F. Clowse M. Criscione-Schreiber L. G. Tochacek M. Monestier M. DS Pisetsky 2011 Cell Death and Anti-DNA AntibodiesJ. Autoimmun. 36 173 180
Pisetsky DS 2012 Cell Death and Anti-DNA AntibodiesArthritis Rheum. 64 958 961
Hughes GR, Cohen SA, Christian CL 1971 Cell Death and Anti-DNA AntibodiesA diagnostic and therapeutic guide. Ann. Rheum. Dis. 30 259 264
Winfield J. B. Faiferman I. Koffler D. 1977 Cell Death and Anti-DNA AntibodiesJ. Clin. Invest. 59 90 96
Madaio M. P. Hodder S. Schwartz R. S. BD Stollar 1984 Cell Death and Anti-DNA AntibodiesJ. Immunol. 132 872 876
Desai DD, Krishnan MR, Swindle JT, Marion TN 1993 Cell Death and Anti-DNA AntibodiesJ. Immunol. 151 1614 1626
Rekvig O. P. Moens U. Fredriksen K. Traavik T. 1997 Cell Death and Anti-DNA AntibodiesMethods 11 44 54
Marchini B. Puccetti A. Dolcher M. P. Madaio M. P. Migliorini P. 1995Induction of anti-DNA antibodies in nonautoimmune mice by immunization with a DNA-DNAase I complex. Clin. Exp. Rheumatol. 13 7 10
Voynova EN, Tchorbanov AI, Todorov TA, Vassilev TL 2005 Cell Death and Anti-DNA Antibodies 14 543 550
Decker P. 2006 Cell Death and Anti-DNA AntibodiesClin. Chim. Acta. 366 48 60
Mohan C. Adams S. Stanik V. Datta S. K. 1993 Cell Death and Anti-DNA AntibodiesJ. Exp. Med. 177 1367 1381
Urbonaviciute V. Fürnrohr B. G. Meister S. Munoz L. Heyder P. De Marchis F. ME Bianchi Kirschning. C. Wagner H. AA Manfredi Kalden. J. R. Schett G. Rovere-Querini P. Herrmann M. Voll R. E. 2008Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J. Exp. Med. 205 3007 3018
Zack D. J. Yamamoto K. Wong A. L. Stempniak M. French C. Weisbart R. H. 1995 Cell Death and Anti-DNA AntibodiesJ. Immunol. 154 1987 1994
Sun KH, Tang SJ, Wang YS, Lin WJ, You RI 2003 Cell Death and Anti-DNA Antibodies 42 154 161
De Giorgio L. A. Konstantinov K. N. Lee S. C. Hardin J. A. Volpe B. T. Diamond B. 2001 Cell Death and Anti-DNA AntibodiesNat. Med. 7 1189 1193
Mostoslavsky G. Fischel R. Yachimovich N. Yarkoni Y. Rosenmann E. Monestier M. Baniyash M. Eilat D. 2001 Cell Death and Anti-DNA AntibodiesEur. J. Immunol. 31 1221 1227
Deocharan B. Qing X. Lichauco J. Putterman C. 2002 Cell Death and Anti-DNA AntibodiesJ. Immunol. 168 3072 3078
Tsuzaka K. Leu A. K. Frank M. B. Movafagh B. F. Koscec M. Winkler T. H. Kalden J. R. Reichlin M. 1996Lupus autoantibodies to double-stranded DNA cross-react with ribosomal protein S1. J. Immunol. 156 1668 1675
Lafer E. M. Rauch J. Andrzejewski C. Mudd D. Furie B. Furie B. Schwartz R. S. BD Stollar 1981Polyspecific monoclonal lupus autoantibodies reactive with both polynucleotides and phospholipids. J. Exp. Med. 153 897 909
Gaynor B. Putterman C. Valadon P. Spatz L. MD Scharff Diamond. B. 1997 Cell Death and Anti-DNA AntibodiesProc. Natl. Acad. Sci. U. S. A. 94 1955 1960
Putterman C. Diamond B. 1998 Cell Death and Anti-DNA AntibodiesJ. Exp. Med. 188 29 38
Yadav P. Tran H. Ebegbe R. Gottlieb P. Wei H. Lewis R. H. Mumbey-Wafula A. Kaplan A. Kholdarova E. Spatz L. 2011Antibodies elicited in response to EBNA-1 may cross-react with dsDNA. PLoS One 6: e14488.
Tamate E. Sasaki T. Muryoi T. Takai O. Otani K. Tada K. Yoshinaga K. 1986 Cell Death and Anti-DNA AntibodiesJ. Immunol. 136 1241 1246
Sasaki T. Hatakeyama A. Shibata S. Osaki H. Suzuki M. Horie K. Kitagawa Y. Yoshinaga K. 1991Heterogeneity of immune complex-derived anti-DNA antibodies associated with lupus nephritis. Kidney Int. 39 746 753
Suzuki M. Hatakeyama A. Kameoka J. Tamate E. Yusa A. Kurosawa K. Saito T. Sasaki T. Yoshinaga K. 1991Anti-DNA idiotypes deposited in renal glomeruli of patients with lupus nephritis. Am. J. Kidney Dis. 18 232 239
Shibata S. Sasaki T. Hatakeyama A. Munakata Y. Hirabayashi Y. Yoshinaga K. 1992 Cell Death and Anti-DNA AntibodiesClin. Immunol. Immunopathol. 63 252 258
Suzuki Y. Funato T. Munakata Y. Sato K. Hirabayashi Y. Ishii T. Takasawa N. Ootaka T. Saito T. Sasaki T. 2000 Cell Death and Anti-DNA AntibodiesJ. Immunol. 165 5900 5905
Hirabayashi Y. Munakata Y. Sasaki T. Sano H. 1992 Cell Death and Anti-DNA AntibodiesNucleic Acids Res. 20: 2601 EOF
Munakata Y. Saito S. Hoshino A. Muryoi T. Hirabayashi Y. Shibata S. Miura T. Ishii T. Funato T. Sasaki T. 1998Somatic mutation in autoantibody-associated VH genes of circulating IgM+IgD+ B cells. Eur. J. Immunol. 28 1435 1444
Hirabayashi Y. Oka Y. Ikeda T. Fujii H. Ishii T. Sasaki T. Harigae H. 2010 Cell Death and Anti-DNA Antibodies 184 3276 3283
Oka Y. Hirabayashi Y. Ishii T. Takahashi R. Sasaki T. 2007 Cell Death and Anti-DNA AntibodiesTohoku J. Exp. Med. 212 431 437
Puthalakath H. O’Reilly L. A. Gunn P. Lee L. Kelly P. N. Huntington N. D. Hughes P. D. Michalak E. M. Mc Kimm-Breschkin J. Motoyama N. Gotoh T. Akira S. Bouillet P. Strasser A. 2007ER stress triggers apoptosis by activating BH3-only protein Bim. Cell 129 1337 1349
Shore GC, Papa FR, Oakes SA 2011 Cell Death and Anti-DNA AntibodiesCurr. Opin. Cell Biol. 23 143 149
Bruns A. Bläss S. Hausdorf G. Burmester G. R. Hiepe F. 2000 Cell Death and Anti-DNA AntibodiesArthritis Rheum. 43 2307 2315
Radic M. Marion T. Monestier M. 2004 Cell Death and Anti-DNA AntibodiesJ. Immunol. 172 6692 6700
Gómez-Puerta J. A. Burlingame R. W. Cervera R. 2008 Cell Death and Anti-DNA AntibodiesAutoimmun. Rev. 7 606 611
van Bruggen M. C. Kramers C. Walgreen B. JD Elema Kallenberg. C. G. van den Born. J. Smeenk R. J. Assmann K. J. Muller S. Monestier M. Berden J. H. 1997Nucleosomes and histones are present in glomerular deposits in human lupus nephritis. Nephrol. Dial. Transplant 12 57 66
O’Flynn J. Flierman R. van der Pol P. Rops A. Satchell S. C. Mathieson P. W. van Kooten C. van der Vlag J. Berden J. H. Daha M. R. 2011Nucleosomes and C1q bound to glomerular endothelial cells serve as targets for autoantibodies and determine complement activation. Mol. Immunol. 49 75 83
Muller S. Dieker J. Tincani A. Meroni P. L. 2008Pathogenic anti-nucleosome antibodies. Lupus 17 431 436
Rubin RL 2005Drug-induced lupus. Toxicology 209 135 147
Marzano A. V. Vezzoli P. Crosti C. 2009 Cell Death and Anti-DNA Antibodies 18 935 940
Lee B. H. Yegnasubramanian S. Lin X. Nelson W. G. 2005 Cell Death and Anti-DNA AntibodiesJ. Biol. Chem. 280 40749 40756
Deng C. Lu Q. Zhang Z. Rao T. Attwood J. Yung R. Richardson B. 2003 Cell Death and Anti-DNA AntibodiesArthritis Rheum. 48 746 756
Strickland FM, Richardson BC 2008 Cell Death and Anti-DNA AntibodiesEpigenetics in DNA methylation in systemic lupus erythematosus and beyond. Autoimmunity 41 278 286
Oka Y. Hirabayashi Y. Ikeda T. Fujii H. Ishii T. Harigae H. 2011 Cell Death and Anti-DNA AntibodiesScand. J. Immunol. 74 296 303
Christen U. von Herrath. M. G. 2004 Cell Death and Anti-DNA AntibodiesCurr. Opin. Immunol. 16 759 767
Wandstrat A. Wakeland E. 2001 Cell Death and Anti-DNA AntibodiesNat. Immunol. 2 802 809
He B. 2006Viruses, endoplasmic reticulum stress, and interferon responses. Cell Death Differ. 13 393 403
Komori R. Taniguchi M. Ichikawa Y. Uemura A. Oku M. Wakabayashi S. Higuchi K. Yoshida H. 2012 Cell Death and Anti-DNA AntibodiesCell Struct. Funct. 37 49 53
James J. A. Kaufman K. M. Farris A. D. Taylor-Albert E. Lehman T. J. Harley J. B. 1997 Cell Death and Anti-DNA AntibodiesJ. Clin. Invest. 100 3019 3026
Niller H. H. Wolf H. Minarovits J. 2008 Cell Death and Anti-DNA Antibodies 41 298 328
Fattal I. Shental N. Mevorach D. Anaya J. M. Livneh A. Langevitz P. Zandman-Goddard G. Pauzner R. Lerner M. Blank M. ME Hincapie Gafter. U. Naparstek Y. Shoenfeld Y. Domany E. Cohen I. R. 2010An antibody profile of systemic lupus erythematosus detected by antigen microarray. Immunology 130 337 343
Kang I. Quan T. Nolasco H. Park S. H. MS Hong Crouch. J. Pamer E. G. Howe J. G. Craft J. 2004Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus. J. Immunol. 172 1287 1294
Larsen M. Sauce D. Deback C. Arnaud L. Mathian A. Miyara M. Boutolleau D. Parizot C. Dorgham K. Papagno L. Appay V. Amoura Z. Gorochov G. 2011Exhausted cytotoxic control of Epstein-Barr virus in human lupus. PLoS Pathog 7: e1002328.
Gross A. J. Hochberg D. Rand W. M. Thorley-Lawson D. A. 2005 Cell Death and Anti-DNA AntibodiesJ. Immunol. 174 6599 6607
Laichalk LL, Thorley-Lawson DA 2005 Cell Death and Anti-DNA AntibodiesJ. Virol. 79 1296 1307
Taylor G. M. Raghuwanshi S. K. Rowe D. T. Wadowsky R. M. Rosendorff A. 2011 Cell Death and Anti-DNA Antibodies 118 5528 5539
Wang H. Nicholas M. W. Conway K. L. Sen P. Diz R. Tisch R. M. Clarke S. H. 2006 Cell Death and Anti-DNA AntibodiesJ. Immunol. 177 2793 2802